157590-59-5

Usage

Uses

Used in Dietary Supplements:
2-Chloro-4,5-diaminobenzotrifluoride is used as an additive in the dietary supplement industry for its potential health benefits. The compound may contribute to enhancing the nutritional value of supplements or serve as an ingredient in the development of novel products aimed at improving overall health and well-being.
Used in Pharmaceutical or Cosmeceuticals:
In the pharmaceutical and cosmeceutical sectors, 2-Chloro-4,5-diaminobenzotrifluoride is utilized as an active ingredient or a key component in the formulation of various products. Its unique chemical properties may offer therapeutic advantages, such as anti-inflammatory, antioxidant, or antimicrobial effects, which can be harnessed for the development of drugs or cosmeceuticals targeting specific health or beauty concerns.
Different applications in different industries may include:
Used in the Pharmaceutical Industry:
2-Chloro-4,5-diaminobenzotrifluoride is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential applications in treating a range of medical conditions, from infectious diseases to chronic illnesses.
Used in the Chemical Industry:
As a versatile intermediate, 2-Chloro-4,5-diaminobenzotrifluoride is employed in the chemical industry for the production of a variety of specialty chemicals, dyes, and pigments. Its reactivity and stability make it a valuable component in the synthesis of complex organic molecules with specific functional groups and properties.
Used in the Agrochemical Industry:
2-Chloro-4,5-diaminobenzotrifluoride may also find applications in the agrochemical industry, where it could be used as a starting material for the development of novel pesticides, herbicides, or other agricultural chemicals. Its unique chemical structure may provide new opportunities for the creation of more effective and environmentally friendly products.

Upstream product

• 167415-22-7 5-Amino-2-chloro-4-nitrobenzotrifluoride 
• 445-13-6 3-chloro-4-(trifluoromethyl)aniline 
• 35375-74-7 5-chloro-2-nitro-4-(trifluoromethyl)aniline 
• 1026318-97-7 N-(5-Chloro-2-nitro-4-trifluoromethyl-phenyl)-acetamide 
• 546434-30-4 acetic acid-(3-chloro-4-trifluoromethyl-anilide) 

Downstream Products

• 1078728-28-5 C₂₁H₁₈ClF₃N₂O₃ 

Relevant academic research and scientific papers

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY

The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.